Degree of Contamination of Gutta-Percha Points by


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
06 Aug 2024
Historique:
received: 05 07 2024
revised: 31 07 2024
accepted: 02 08 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Methicillin-resistant We performed an in vitro analysis of the contamination of GP points, regarding the strains of Methicillin-resistant (MRSA) and Methicillin-sensitive (MSSA) Gutta-Percha points of two different brands from opened packages (already in use for 1 month) were collected for analysis. The assessment involved incubating the GP points in Brain Heart Infusion (BHI) medium to detect microbial growth. Growing microorganisms were plated on a selective and differential chromogenic medium for MRSA/MSSA strains, and the identification of isolates was confirmed by Polymerase Chain Reaction (PCR). In the case of microbial growth, the GP point was submitted to a disinfection protocol. From the 315 collected GP points, only 6 (1.9%) resulted in being positive for microbial growth. After confirmation by PCR, only one sample of the six GP points was contaminated by MRSA, and the remaining five were MSSA-contaminated. The disinfection protocol was effective in all contaminated GP points. The Gutta-Percha points from opened pre-sterilized packages showed a very low degree of contamination by MRSA/MSSA. However, the detection of MSSA and MRSA strains raises concerns about potential contamination in dental clinic environments, and this risk cannot be considered negligible.

Identifiants

pubmed: 39201252
pii: ijms25168566
doi: 10.3390/ijms25168566
pii:
doi:

Substances chimiques

Gutta-Percha 9000-32-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Fundação para a Ciência e a Tecnologia (FCT)
ID : UIDB/04279/2020 and UIDP/04279/2020

Auteurs

Ana Moura Teles (AM)

Faculty of Dental Medicine, Universidade Católica Portuguesa, 3504-505 Viseu, Portugal.
Centre for Interdisciplinary Research in Health (CIIS), Universidade Católica Portuguesa, 3504-505 Viseu, Portugal.

Cristina Pina (C)

FCS-UFP, Universidade Fernando Pessoa, Faculdade de Ciências da Saúde, 4200-150 Porto, Portugal.
FP-I3ID, Instituto de Investigação, Inovação e Desenvolvimento, FP-BHS, Universidade Fernando Pessoa, Biomedical and Health Sciences, 4249-004 Porto, Portugal.
CINTESIS.UFP@RISE, Centro de Investigação em Tecnologias e Serviços de Saúde, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4200-450 Porto, Portugal.

Inês Lopes Cardoso (IL)

FCS-UFP, Universidade Fernando Pessoa, Faculdade de Ciências da Saúde, 4200-150 Porto, Portugal.
FP-I3ID, Instituto de Investigação, Inovação e Desenvolvimento, FP-BHS, Universidade Fernando Pessoa, Biomedical and Health Sciences, 4249-004 Porto, Portugal.
CINTESIS.UFP@RISE, Centro de Investigação em Tecnologias e Serviços de Saúde, Rede de Investigação em Saúde, Universidade Fernando Pessoa, 4200-450 Porto, Portugal.

Antea Tramontana (A)

FCS-UFP, Universidade Fernando Pessoa, Faculdade de Ciências da Saúde, 4200-150 Porto, Portugal.

Miguel Cardoso (M)

Faculty of Dental Medicine, Universidade Católica Portuguesa, 3504-505 Viseu, Portugal.

Ana Sofia Duarte (AS)

Faculty of Dental Medicine, Universidade Católica Portuguesa, 3504-505 Viseu, Portugal.
Centre for Interdisciplinary Research in Health (CIIS), Universidade Católica Portuguesa, 3504-505 Viseu, Portugal.

Maria Bartolomeu (M)

Faculty of Dental Medicine, Universidade Católica Portuguesa, 3504-505 Viseu, Portugal.
Centre for Interdisciplinary Research in Health (CIIS), Universidade Católica Portuguesa, 3504-505 Viseu, Portugal.

Rita Noites (R)

Faculty of Dental Medicine, Universidade Católica Portuguesa, 3504-505 Viseu, Portugal.
Centre for Interdisciplinary Research in Health (CIIS), Universidade Católica Portuguesa, 3504-505 Viseu, Portugal.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH